Do specific HbA1c thresholds and the Atherogenic Index of Plasma (AIP) improve cardiovascular risk reclassification in adults with type 2 diabetes not on lipid-lowering therapy?
271 adults with type 2 diabetes not receiving lipid-lowering therapy
HbA1c levels (good <7.0%, moderate 7.0%-8.49%, poor ≥8.5%)
Comparisons across different HbA1c control groups
Atherogenic lipid burden (evaluated using Atherogenic Index of Plasma [AIP], Castelli indices, TG/HDL-C, non-HDL cholesterol, and remnant cholesterol) and cardiovascular risk reclassification (Net Reclassification Improvement [NRI])surrogate
An HbA1c of 8.0%-8.5% represents a metabolically vulnerable threshold for accelerated atherogenic dyslipidemia in type 2 diabetes, where adding the Atherogenic Index of Plasma improves cardiovascular risk reclassification.
Dysglycemia, lipid metabolism, and cardiovascular disease (CVD) progression in type 2 diabetes (T2D) are closely interconnected, yet the non-linear lipid remodeling processes underlying atherogenic dyslipidemia remain insufficiently defined. This study aimed to identify HbA1c thresholds associated with accelerated lipid-driven atherogenesis, quantify the mediating role of the triglyceride-to-HDL cholesterol ratio (TG/HDL-C) -a surrogate of insulin-resistance-related lipid metabolism-and assess the incremental predictive value of the Atherogenic Index of Plasma (AIP) within the clinically ambiguous "glycemic gray zone. " A total of 271 adults with T2D not receiving lipid-lowering therapy were retrospectively grouped by HbA1c: good (NRI) tested the added predictive value of AIP over conventional lipid markers. All atherogenic indices worsened with deteriorating glycemia (p < 0. 001). Non-linear inflection points were observed at HbA1c 8. 0% for TG/HDL-C and 8. 5% for AIP (pₙon-linearity < 0. 01). TG/HDL-C mediated 56. 9% of the HbA1c effect on AIP, indicating its central role in linking hyperglycemia to lipid remodeling. Adding AIP improved cardiovascular risk reclassification, particularly in the 8. 0%-8. 5% transition range (categorical NRI = 0. 384; 95% CI: 0. 184-0. 584). These findings identify 8. 0%-8. 5% as a metabolically vulnerable HbA1c threshold marked by accelerated atherogenic dyslipidemia. AIP functions as a sensitive lipid-based marker for cardiometabolic risk detection within this gray zone, while TG/HDL-C acts as a key mechanistic mediator, supporting the integration of atherogenic lipid indices into individualized risk assessment and precision lipid management strategies in T2D.
Building similarity graph...
Analyzing shared references across papers
Loading...
Vehbi Şirikçi
Directorate of Health
Murat Erdoğan
Ondokuz Mayıs University
SHILAP Revista de lepidopterología
Frontiers in Cardiovascular Medicine
Kahramanmaraş Sütçü İmam University
Building similarity graph...
Analyzing shared references across papers
Loading...
Şirikçi et al. (Fri,) studied this question.
synapsesocial.com/papers/69a75e8bc6e9836116a29406 — DOI: https://doi.org/10.3389/fcvm.2026.1751404
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: